Procter & Gamble insider filing: 714 shares to be sold on NYSE

Rhea-AI Filing Summary

Procter & Gamble Form 144 notice reports a proposed sale of 714 shares of common stock, with an aggregate market value of $110,602.17, to be sold on the NYSE on or about 08/19/2025. The shares were acquired on 08/18/2025 under a Performance Stock Program Award from The Procter & Gamble Company and were paid for on 08/18/2025. The filing lists total shares outstanding of 2,342,371,488, indicating the sale is immaterial relative to the companys total float. The filer certifies they are unaware of any undisclosed material adverse information and provides standard Rule 144 representations regarding trading plans and compliance.

Insights

Securities Analyst

TL;DR: Small insider sale from a performance award; immaterial to capitalization and likely routine compliance with Rule 144.

The Form 144 notifies the market of a proposed sale of 714 shares valued at $110,602.17, to be executed on the NYSE around 08/19/2025. The shares were granted and acquired the day before sale under a Performance Stock Program Award. Given the issuers 2.34 billion shares outstanding, this sale represents a de minimis transfer and is typically administrative in nature. The filers certification that no material nonpublic information is known is standard language for such notices.

Corporate Governance Expert

TL;DR: Routine disclosure consistent with insider sale rules; no governance red flags in the form itself.

The filing complies with Rule 144 reporting by disclosing acquisition date, nature of acquisition (Performance Stock Program Award), broker details (Morgan Stanley Smith Barney LLC Executive Financial Services), approximate sale date, and exchange. The absence of other recent sales reported in the past three months and the declarative statement about no undisclosed material information are normal. There are no indicators of unusual timing or large insider divestiture in this notice.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 38th Floor New York NY 10004	714	110602.17	2342371488	08/19/2025	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	08/18/2025	Performance Stock Program Award	The Procter & Gamble Company			2005	08/18/2025	NA

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does Procter & Gamble's (PG) Form 144 report?

The filing reports a proposed sale of 714 common shares valued at $110,602.17 to be sold on the NYSE on or about 08/19/2025.

How and when were the shares acquired according to the Form 144?

The shares were acquired on 08/18/2025 under a Performance Stock Program Award from The Procter & Gamble Company, with payment dated 08/18/2025.

Who is the broker named in the filing?

The broker listed is Morgan Stanley Smith Barney LLC Executive Financial Services, located at 1 New York Plaza, 38th Floor, New York, NY.

How material is the sale relative to PG's outstanding shares?

The filing shows 2,342,371,488 shares outstanding, so the proposed sale of 714 shares is immaterial relative to total capitalization.

Does the filer state any undisclosed material information?

The filer represents by signature that they do not know of any material adverse information about the issuer that has not been publicly disclosed.